ITCI Intra-Cellular Therapies | $126.20
0.0% | 1/13/2025 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Intra-Cellular Therapies (NASDAQ:ITCI) on 1/13/2025 |
ACCD Accolade | $6.89
+0.4% | 1/8/2025 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Accolade (NASDAQ:ACCD) on 1/8/2025 |
DGX Quest Diagnostics | $151.31
-0.2% | 1/6/2025 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Hold -> Strong-Buy | | Medium | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 1/6/2025 |
ALGN Align Technology | $224.23
+2.4% | 1/6/2025 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 1/6/2025 |
QTTB Q32 Bio | $3.28
+4.5% | 12/11/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 12/11/2024 |
PDCO Patterson Companies | $30.90
+0.1% | 12/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 12/11/2024 |
ANIP ANI Pharmaceuticals | $58.46
+1.7% | 12/11/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | N/A | View details for Leerink Partnrs rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/11/2024 |
MYGN Myriad Genetics | $12.39
-1.0% | 12/9/2024 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 12/9/2024 |
RLMD Relmada Therapeutics | $0.37
-1.7% | 12/4/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Relmada Therapeutics (NASDAQ:RLMD) on 12/4/2024 |
OKUR OnKure Therapeutics | $5.79
-3.7% | 12/5/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy | | N/A | View details for Leerink Partnrs rating of OnKure Therapeutics (NASDAQ:OKUR) on 12/5/2024 |
|
ZTS Zoetis | $166.01
-2.0% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Zoetis (NYSE:ZTS) on 12/2/2024 |
IDXX IDEXX Laboratories | $419.26
-2.2% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Strong-Buy | | N/A | View details for Leerink Partnrs rating of IDEXX Laboratories (NASDAQ:IDXX) on 12/2/2024 |
ELAN Elanco Animal Health | $12.03
+0.1% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst D. Clark | Hold | | N/A | View details for Leerink Partnrs rating of Elanco Animal Health (NYSE:ELAN) on 12/2/2024 |
CLYM Climb Bio | $1.95
-3.0% | 12/2/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Climb Bio (NASDAQ:CLYM) on 12/2/2024 |
JANX Janux Therapeutics | $40.72
+0.3% | 11/22/2024 | Upgraded by | Leerink Partnrs | Analyst J. La. Rosa | Strong-Buy | | N/A | View details for Leerink Partnrs rating of Janux Therapeutics (NASDAQ:JANX) on 11/22/2024 |
ABBV AbbVie | $171.49
-1.3% | 11/22/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of AbbVie (NYSE:ABBV) on 11/22/2024 |
ACRS Aclaris Therapeutics | $2.57
+2.4% | 11/19/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $2.60
+4.0% | 11/15/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
MASS 908 Devices | $2.98
+2.8% | 11/13/2024 | Downgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
BMY Bristol-Myers Squibb | $56.35
0.0% | 11/12/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Bristol-Myers Squibb (NYSE:BMY) on 11/12/2024 |
XRAY DENTSPLY SIRONA | $18.77
+1.8% | 11/7/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | N/A | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $13.88
-0.8% | 11/7/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $23.44
+0.2% | 11/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Hold -> Strong-Buy | | N/A | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $22.18
-2.4% | 11/5/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $1.77
-1.7% | 11/4/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $19.83
+3.3% | 10/31/2024 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Strong Sell -> Hold | | Medium | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 10/31/2024 |
TENX Tenax Therapeutics | $6.33
-1.2% | 10/24/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | High | View details for Leerink Partnrs rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $91.84
+0.2% | 10/21/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Hold -> Strong-Buy | | High | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
VYGR Voyager Therapeutics | $5.07
+0.2% | 10/16/2024 | Upgraded by | Leerink Partnrs | Analyst L. Nsongo | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
STOK Stoke Therapeutics | $9.36
-1.1% | 10/11/2024 | Upgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy | | Low | View details for Leerink Partnrs rating of Stoke Therapeutics (NASDAQ:STOK) on 10/11/2024 |
MNMD Mind Medicine (MindMed) | $7.16
+10.0% | 10/11/2024 | Upgraded by | Leerink Partnrs | Analyst M. Goodman | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/11/2024 |
MOLN Molecular Partners | $5.36
-7.8% | 10/7/2024 | Upgraded by | Leerink Partnrs | Analyst J. Chang | Strong-Buy | | Low | View details for Leerink Partnrs rating of Molecular Partners (NASDAQ:MOLN) on 10/7/2024 |
HUM Humana | $282.63
+2.5% | 10/2/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Humana (NYSE:HUM) on 10/2/2024 |
AGIO Agios Pharmaceuticals | $32.42
+1.9% | 9/27/2024 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $681.58
-1.7% | 9/24/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Medium | View details for Leerink Partnrs rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
ICLR ICON Public | $198.11
-2.2% | 9/18/2024 | Upgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy | | Low | View details for Leerink Partnrs rating of ICON Public (NASDAQ:ICLR) on 9/18/2024 |
ORKA Oruka Therapeutics | $12.25
-2.8% | 9/17/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | Low | View details for Leerink Partnrs rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $3.96
-0.5% | 9/12/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Strong-Buy -> Hold | | High | View details for Leerink Partnrs rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
TRVI Trevi Therapeutics | $3.76
-0.5% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
PRTC PureTech Health | $18.04
-0.3% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
Buy this coin BEFORE Inauguration Day … (Ad) Mark my words … Bitcoin is going to $100,000.
BEFORE Trump is inaugurated.
And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. |
PLRX Pliant Therapeutics | $11.21
-3.4% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
MNKD MannKind | $6.01
| 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
KYMR Kymera Therapeutics | $40.61
+0.8% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Medium | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $3.66
-3.2% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Hold | | Medium | View details for Leerink Partnrs rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
IMUX Immunic | $0.95
-3.4% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | High | View details for Leerink Partnrs rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
GLPG Galapagos | $23.76
-0.6% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Hold | | Medium | View details for Leerink Partnrs rating of Galapagos (NASDAQ:GLPG) on 9/9/2024 |
GERN Geron | $2.89
-1.0% | 9/9/2024 | Upgraded by | Leerink Partnrs | Analyst F. Khurshid | Strong-Buy | | Low | View details for Leerink Partnrs rating of Geron (NASDAQ:GERN) on 9/9/2024 |
TXG 10x Genomics | $15.08
-0.1% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy | | Low | View details for Leerink Partnrs rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
PEN Penumbra | $264.08
+0.7% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Strong-Buy | | Low | View details for Leerink Partnrs rating of Penumbra (NYSE:PEN) on 9/3/2024 |
NARI Inari Medical | $79.55
+0.2% | 9/3/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Hold | | Low | View details for Leerink Partnrs rating of Inari Medical (NASDAQ:NARI) on 9/3/2024 |
ARDT Ardent Health Partners | $14.10
+2.1% | 8/12/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Ardent Health Partners (NYSE:ARDT) on 8/12/2024 |
ARCT Arcturus Therapeutics | $16.79
-1.3% | 8/12/2024 | Upgraded by | Leerink Partnrs | Analyst L. Nsongo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $21.00
+1.8% | 8/7/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $8.58
+1.7% | 8/6/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
WAT Waters | $403.85
-0.4% | 8/1/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $40.90
-2.7% | 7/24/2024 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy | | Low | View details for Leerink Partnrs rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $31.43
-2.6% | 7/24/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $7.66
-1.7% | 7/23/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | Low | View details for Leerink Partnrs rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $10.93
-2.8% | 7/22/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Strong-Buy | | Low | View details for Leerink Partnrs rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $10.30
-6.9% | 7/22/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Strong-Buy | | Low | View details for Leerink Partnrs rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
EHC Encompass Health | $94.68
+0.3% | 7/10/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy | | Low | View details for Leerink Partnrs rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $1.90
+0.5% | 7/9/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
RVTY Revvity | $118.29
-1.0% | 7/8/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Strong-Buy | | Low | View details for Leerink Partnrs rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrödinger | $19.00
+1.7% | 7/2/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Strong-Buy | | Low | View details for Leerink Partnrs rating of Schrödinger (NASDAQ:SDGR) on 7/2/2024 |
SLDB Solid Biosciences | $3.27
+0.6% | 6/24/2024 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Hold -> Strong-Buy | | Low | View details for Leerink Partnrs rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
QTTB Q32 Bio | $3.28
+4.5% | 5/21/2024 | Upgraded by | Leerink Partnrs | Analyst T. Smith | Strong-Buy | | Low | View details for Leerink Partnrs rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.51
-1.6% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/14/2024 |
EHAB Enhabit | $7.99
+0.2% | 5/14/2024 | Upgraded by | Leerink Partnrs | Analyst W. Mayo | Strong Sell -> Hold | | Low | View details for Leerink Partnrs rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AIRS AirSculpt Technologies | $5.33
+8.1% | 5/14/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Strong-Buy -> Hold | | Low | View details for Leerink Partnrs rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
AQST Aquestive Therapeutics | $3.10
+0.3% | 5/10/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Strong-Buy | | Low | View details for Leerink Partnrs rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $12.39
-1.0% | 5/8/2024 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $110.05
+5.9% | 5/6/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Underperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $52.72
+1.5% | 5/1/2024 | Downgraded by | Leerink Partnrs | Analyst M. Cherny | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 5/1/2024 |
XOMA XOMA | $26.76
-1.9% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
LXRX Lexicon Pharmaceuticals | $0.69
-3.3% | 4/30/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
IMCR Immunocore | $29.02
-0.3% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
NGNE Neurogene | $16.60
-5.8% | 4/29/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
TNDM Tandem Diabetes Care | $35.15
-6.3% | 4/25/2024 | Upgraded by | Leerink Partnrs | Analyst M. Kratky | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
CVAC CureVac | $4.10
-1.9% | 4/25/2024 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
RNAC Cartesian Therapeutics | $19.29
+1.9% | 4/23/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $15.85
+5.5% | 4/16/2024 | Reiterated by | Leerink Partnrs | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partnrs rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.16
+10.0% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst R. Li | Outperform | | Low | View details for Leerink Partnrs rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $22.50
+0.4% | 4/15/2024 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $5.01
-2.9% | 4/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $3.34
+2.8% | 4/3/2024 | Reiterated by | Leerink Partnrs | Analyst J. Park | Outperform | | Low | View details for Leerink Partnrs rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $75.84
-0.2% | 4/1/2024 | Upgraded by | Leerink Partnrs | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.39
+2.8% | 3/25/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
RGLS Regulus Therapeutics | $1.24
-3.1% | 3/18/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.36
-4.8% | 3/14/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $3.60
+2.9% | 3/11/2024 | Downgraded by | Leerink Partnrs | Analyst M. Goodman | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
Buy this coin BEFORE Inauguration Day … (Ad) Mark my words … Bitcoin is going to $100,000.
BEFORE Trump is inaugurated.
And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. |
RGNX REGENXBIO | $7.37
+3.1% | 3/6/2024 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $12.57
+3.2% | 3/5/2024 | Upgraded by | Leerink Partnrs | Analyst R. Ruiz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $3.33
-2.9% | 3/4/2024 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
IDYA IDEAYA Biosciences | $22.18
-2.4% | 2/23/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 2/23/2024 |
DOCS Doximity | $53.78
+1.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $11.66
-0.9% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Certara (NASDAQ:CERT) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $18.77
+1.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RLAY Relay Therapeutics | $4.46
+3.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 2/22/2024 |
PGNY Progyny | $21.00
+1.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
NVST Envista | $19.83
+3.3% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Underperform | | Low | View details for Leerink Partnrs rating of Envista (NYSE:NVST) on 2/26/2024 |
NUVL Nuvalent | $75.84
-0.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 2/22/2024 |
LH Laboratory Co. of America | $238.44
-0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
DGX Quest Diagnostics | $151.31
-0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
COGT Cogent Biosciences | $8.03
-1.2% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Cogent Biosciences (NASDAQ:COGT) on 2/22/2024 |
ARVN Arvinas | $18.05
+2.7% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Arvinas (NASDAQ:ARVN) on 2/22/2024 |
ALGN Align Technology | $224.23
+2.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $6.89
+0.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
WBA Walgreens Boots Alliance | $12.52
-3.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
TDOC Teladoc Health | $9.10
-0.7% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
PINC Premier | $22.43
+1.8% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Market Perform | | Low | View details for Leerink Partnrs rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $30.90
+0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $14.55
+0.1% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $592.69
-0.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of McKesson (NYSE:MCK) on 2/26/2024 |
IQV IQVIA | $197.25
-0.2% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HSIC Henry Schein | $73.22
+2.0% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
HIMS Hims & Hers Health | $27.80
-0.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Market Perform | | Low | View details for Leerink Partnrs rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.57
+3.4% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst S. Davis | Outperform | | Low | View details for Leerink Partnrs rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
CVS CVS Health | $52.72
+1.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of CVS Health (NYSE:CVS) on 2/26/2024 |
COR Cencora | $242.11
+0.5% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $126.27
-0.6% | 2/26/2024 | Reiterated by | Leerink Partnrs | Analyst M. Cherny | Outperform | | Low | View details for Leerink Partnrs rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
APLT Applied Therapeutics | $0.65
+5.3% | 2/22/2024 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Outperform | | Low | View details for Leerink Partnrs rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $1.20
+0.8% | 2/21/2024 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
ENGN enGene | $7.14
+1.9% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
BTSG BrightSpring Health Services | $18.55
+0.4% | 2/20/2024 | Reiterated by | Leerink Partnrs | Analyst W. Mayo | Outperform | | Low | View details for Leerink Partnrs rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
SYBX Synlogic | $1.45
| 2/9/2024 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $272.11
+1.0% | 2/7/2024 | Downgraded by | Leerink Partnrs | Analyst D. Risinger | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $358.93
-2.0% | 2/5/2024 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $2.61
+7.0% | 1/31/2024 | Upgraded by | Leerink Partnrs | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $11.97
+0.5% | 1/30/2024 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $9.99
+1.3% | 1/29/2024 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Outperform | | Low | View details for Leerink Partnrs rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $1.50
+2.0% | 1/23/2024 | Reiterated by | Leerink Partnrs | Analyst J. La. Rosa | Outperform | | Low | View details for Leerink Partnrs rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AGL agilon health | $3.12
+5.2% | 1/8/2024 | Downgraded by | Leerink Partnrs | Analyst W. Mayo | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $9.28
+3.1% | 12/22/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $10.99
-2.8% | 12/19/2023 | Upgraded by | Leerink Partnrs | Analyst J. Schwartz | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
NBTX Nanobiotix | $3.03
+2.4% | 12/8/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TRML Tourmaline Bio | $18.00
+3.9% | 12/7/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Tourmaline Bio (NASDAQ:TRML) on 12/7/2023 |
MOR MorphoSys | $18.96
| 12/6/2023 | Reiterated by | Leerink Partnrs | Analyst A. Berens | Market Perform | | Low | View details for Leerink Partnrs rating of MorphoSys (NASDAQ:MOR) on 12/6/2023 |
TNYA Tenaya Therapeutics | $1.40
+0.7% | 11/30/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $5.07
-2.3% | 11/28/2023 | Reiterated by | Leerink Partnrs | Analyst M. Foroohar | Outperform | | Low | View details for Leerink Partnrs rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $6.16
-1.1% | 11/14/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
Buy this coin BEFORE Inauguration Day … (Ad) Mark my words … Bitcoin is going to $100,000.
BEFORE Trump is inaugurated.
And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. |
ACRS Aclaris Therapeutics | $2.57
+2.4% | 11/13/2023 | Downgraded by | Leerink Partnrs | Analyst T. Smith | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/13/2023 |
ZNTL Zentalis Pharmaceuticals | $2.24
-6.3% | 11/7/2023 | Downgraded by | Leerink Partnrs | Analyst A. Berens | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $2.61
+7.0% | 10/30/2023 | Downgraded by | Leerink Partnrs | Analyst D. Graybosch | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $23.44
+0.2% | 10/20/2023 | Downgraded by | Leerink Partnrs | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $4.58
-2.1% | 10/18/2023 | Upgraded by | Leerink Partnrs | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
PLRX Pliant Therapeutics | $11.21
-3.4% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Outperform | | Low | View details for Leerink Partnrs rating of Pliant Therapeutics (NASDAQ:PLRX) on 10/16/2023 |
KYMR Kymera Therapeutics | $40.61
+0.8% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst T. Smith | Market Perform | | Low | View details for Leerink Partnrs rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/16/2023 |
VCEL Vericel | $59.07
+4.8% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
TNDM Tandem Diabetes Care | $35.15
-6.3% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $76.02
-3.6% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
PODD Insulet | $275.81
+1.1% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
INSP Inspire Medical Systems | $177.97
+2.4% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
EW Edwards Lifesciences | $69.77
-0.1% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Market Perform | | Low | View details for Leerink Partnrs rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
DXCM DexCom | $84.38
-0.5% | 10/16/2023 | Reiterated by | Leerink Partnrs | Analyst M. Kratky | Outperform | | Low | View details for Leerink Partnrs rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
GILD Gilead Sciences | $91.84
+0.2% | 10/11/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Gilead Sciences (NASDAQ:GILD) on 10/11/2023 |
AMGN Amgen | $272.11
+1.0% | 10/11/2023 | Upgraded by | Leerink Partnrs | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
ACLX Arcellx | $66.48
-0.8% | 10/12/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partnrs rating of Arcellx (NASDAQ:ACLX) on 10/12/2023 |
SPRY ARS Pharmaceuticals | $12.57
+3.2% | 9/21/2023 | Downgraded by | Leerink Partnrs | Analyst R. Ruiz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
TSBX Turnstone Biologics | $0.44
-4.8% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst D. Graybosch | Market Perform | | Low | View details for Leerink Partnrs rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 |
DSGN Design Therapeutics | $5.06
+6.8% | 8/15/2023 | Downgraded by | Leerink Partnrs | Analyst J. Schwartz | Outperform -> Market Perform | | Low | View details for Leerink Partnrs rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $45.74
-2.7% | 8/15/2023 | Reiterated by | Leerink Partnrs | Analyst R. Ruiz | Outperform | | Low | View details for Leerink Partnrs rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
RLAY Relay Therapeutics | $4.46
+3.2% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $75.84
-0.2% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $22.18
-2.4% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Outperform | | Low | View details for Leerink Partnrs rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $36.20
-1.0% | 8/8/2023 | Reiterated by | Leerink Partnrs | Analyst C. Liu | Market Perform | | Low | View details for Leerink Partnrs rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $8.87
+0.6% | 8/8/2023 | Upgraded by | Leerink Partnrs | Analyst P. Souda | Market Perform -> Outperform | | Low | View details for Leerink Partnrs rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $26.17
+0.6% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Chang | Outperform | | Low | View details for Leerink Partnrs rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
WVE Wave Life Sciences | $10.99
-2.8% | 8/4/2023 | Reiterated by | Leerink Partnrs | Analyst J. Schwartz | Market Perform | | Low | View details for Leerink Partnrs rating of Wave Life Sciences (NASDAQ:WVE) on 8/4/2023 |
BLTE Belite Bio | $56.21
+6.0% | 7/26/2023 | Reiterated by | Leerink Partnrs | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partnrs rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
